×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRSP – crispr therapeutics ag - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRSP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
6/12
07:00 am
crsp
CRISPR Therapeutics (CRSP) was given a new $80.00 price target by UBS Group AG.
Low
Report
CRISPR Therapeutics (CRSP) was given a new $80.00 price target by UBS Group AG.
6/11
07:00 am
crsp
CRISPR Therapeutics (CRSP) was given a new $60.00 price target by Morgan Stanley.
Low
Report
CRISPR Therapeutics (CRSP) was given a new $60.00 price target by Morgan Stanley.
6/8
01:24 pm
crsp
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? [Globe and Mail, The (Toronto, Canada)]
Low
Report
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? [Globe and Mail, The (Toronto, Canada)]
6/8
01:22 pm
crsp
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? [Yahoo! Finance]
Low
Report
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? [Yahoo! Finance]
6/5
08:27 pm
crsp
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline [Yahoo! Finance]
Low
Report
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline [Yahoo! Finance]
6/5
04:44 am
crsp
[Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]
Medium
Report
[Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]
6/5
04:44 am
crsp
Eli Lilly Pressure And RNA Expansion Reframe CRISPR Therapeutics Outlook [Yahoo! Finance]
Medium
Report
Eli Lilly Pressure And RNA Expansion Reframe CRISPR Therapeutics Outlook [Yahoo! Finance]
6/5
04:44 am
crsp
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report? [Yahoo! Finance]
Medium
Report
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
5/4/2026
04:30 pm
crsp
crispr therapeutics ag - common shares
MISS
Report
-1.0%
crispr therapeutics ag - common shares
2/12/2026
04:30 pm
crsp
crispr therapeutics ag - common shares
MISS
Report
10.1%
crispr therapeutics ag - common shares
11/10/2025
08:00 am
crsp
crispr therapeutics ag - common shares
BEAT
Report
-6.2%
crispr therapeutics ag - common shares
8/4/2025
04:15 pm
crsp
crispr therapeutics ag - common shares
MISS
Report
-7.1%
crispr therapeutics ag - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
5/27
07:00 am
Reiterates
Market Outperform
Market Outperform
Citigroup Inc.
Medium
Report
3.9%
Date
Time
Symbol
Headline
Impact
6/9
06:09 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: George Simeon
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: George Simeon
6/9
06:06 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Behbahani Ali
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Behbahani Ali
6/9
05:44 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fardis Maria
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fardis Maria
6/9
05:43 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Greene John
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Greene John
6/9
05:43 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fleming Harold Edward
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fleming Harold Edward
6/9
05:42 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Mahatme Sandesh
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Mahatme Sandesh
6/9
05:42 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: High Katherine A
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: High Katherine A
6/9
05:41 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Morrison Briggs
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Morrison Briggs
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
CRISPR Therapeutics down 4% premarket on initial CTX001 data [Seeking Alpha]
19.1%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
TOP News Decliners
11/20
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
-10.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: